Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clobazam
Drug ID BADD_D00488
Description Clobazam belongs to the 1,5-benzodiazepine class of drugs and is expected to have a better side-effect profile compared to older 1,4-benzodiazepines. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. The oral preparation was FDA approved on October 21, 2011. An oral suspension is expected to be available in 2013.
Indications and Usage For treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy.
Marketing Status Prescription; Discontinued
ATC Code N05BA09
DrugBank ID DB00349
KEGG ID D01253
MeSH ID D000078306
PubChem ID 2789
TTD Drug ID D0S9MC
NDC Product Code 67386-313; 64330-110; 69766-016; 51672-4203; 0054-0561; 11014-0115; 82348-103; 72606-003; 69452-115; 42571-316; 67877-666; 51672-4210; 70710-1326; 51672-4202; 68180-157; 16714-087; 69238-1305; 51672-4227; 67877-665; 11014-0114; 69037-0009; 13632-313; 66689-058; 59651-401; 69238-1535; 0832-0585; 65085-0054; 70771-1441; 70710-1325; 47621-047; 67877-658; 69539-153; 67386-314; 68180-156; 0527-1681; 60687-423; 12828-0084; 68180-158; 31722-639; 31722-640; 10094-205; 69539-154; 70771-1440; 0832-0581; 16714-887; 72606-004; 0378-8043; 0832-0580; 42571-315; 69452-114; 0781-8013; 0054-0526; 51991-900; 51991-901; 42571-308; 0527-1682; 48087-0094; 10094-210; 0527-5301; 69238-1306; 69452-116; 16714-888; 67386-315; 0781-8014; 10094-220; 31722-641; 0054-0527; 48087-0117
Synonyms Clobazam | Urbanyl | Onfi | 1-Phenyl-5-methyl-8-chloro-1,2,4,5- tetrahydro-2,4-diketo-3H-1,5-benzodiazepine | HR 376 | LM-2717 | LM 2717 | LM2717 | Frisium
Chemical Information
Molecular Formula C16H13ClN2O2
CAS Registry Number 22316-47-8
SMILES CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Psychomotor retardation19.15.02.0020.000602%Not Available
Purpura01.01.04.003; 24.07.06.005; 23.06.01.0040.000602%
Pyloric stenosis07.13.04.001; 03.04.05.0010.000157%Not Available
Pyrexia08.05.02.0030.004214%
Rash23.03.13.0010.009030%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.000236%Not Available
Respiratory disorder22.02.07.0020.000602%Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Salivary hypersecretion07.06.01.0090.000602%Not Available
Sedation17.02.04.0050.012040%Not Available
Seizure17.12.03.0010.031605%
Sepsis11.01.11.003--
Skin disorder23.03.03.007--Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000602%Not Available
Somnolence19.02.05.003; 17.02.04.0060.010535%
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.0030.000602%Not Available
Staring19.01.01.0030.000602%Not Available
Status epilepticus17.12.03.0050.003311%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.0200.000903%
Suicidal ideation19.12.01.0030.001505%
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tic19.11.04.001; 17.02.05.0240.000602%Not Available
Tonic convulsion17.12.03.0110.000602%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary retention20.02.02.0110.004515%
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages